Navigation Links
New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies
Date:7/24/2014

Bethesda, MD (PRWEB) July 24, 2014

The first-ever successful isolation and culture of rare tumor cells circulating in a patient’s blood has been achieved by NFCR-supported scientist Daniel Haber, M.D., Ph.D., and his team at Massachusetts General Hospital. This is an important milestone on the road to individualized cancer therapy, a new approach to selecting the best treatment for each patient.

“Tumors evolve in response to treatment,” said Dr. Haber. “They often acquire new genetic features that make them resistant to drugs. If we can monitor those changes in real time, we stand a better chance of matching the right treatments with the right patients against those new changes in their tumors.” With the success of the CTC-iChip, it is now possible to do just that.

The CTC-iChip is a business card-sized device developed by MGH bioengineer Dr. Mehmet Toner, Dr. Haber and their collaborators that can capture extraordinarily rare “circulating tumor cells” (CTCs) from a patient’s blood sample – one tumor cell per billion blood cells. Recent improvements in the chip make it easier to remove CTCs from the filter device and grow them in cell culture dishes in the labs.

As part of the experiment, the researchers took multiple blood samples from women with breast cancer over the course of their treatment, and were able to monitor the development of new mutations in their CTCs. Because this approach starts with a simple blood test, changes in the tumor cells can be assessed over time without the need for repeated, invasive, and painful biopsies.

Using the CTC-derived tumor models grown in the lab, Dr. Haber’s team could also test various combinations of drugs to see which were effective. This technique could provide a new way to help physicians develop personalized cancer treatment plans for individual patients. Dr. Haber and his team are now focused on optimizing CTC culture conditions, improving efficiency, bringing down costs, and meeting the remaining challenges to bring individualized therapy into the clinic.

“At NFCR we take the long view of cancer research, and our support of Dr. Haber’s research over the past decade is paying off,” said Franklin Salisbury, Jr., President of NFCR. “We could not be more proud of what Dr. Haber and his colleagues at MGH have accomplished, and we have every confidence that they will continue to improve this technique, making individualized therapy a reality for cancer patients everywhere.”

Dr. Haber has received NFCR support since 2003. Dr. Haber’s findings were published in the July 11 issue of the journal Science.

About the National Foundation for Cancer Research

The National Foundation for Cancer Research (NFCR) is a leading cancer research charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, a cure for cancer. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. NFCR is committed to Research for a Cure - cures for all types of cancer. For more information, visit http://www.nfcr.org/ or call (800) 321-CURE (2873).

Read the full story at http://www.prweb.com/releases/2014/07/prweb12042342.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. High Blood Pressure May Be Especially Lethal for Blacks
6. Changes in gene expression may help explain high blood pressure in pregnancy
7. Researchers Develop Blood Test for Depression
8. Naturopathic care can improve blood sugar, mood in diabetes
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Exercise May Help Patients With High Blood Pressure Live Longer
11. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... clinical outcomes, hosted members and suppliers for its inaugural Member Conference at the ... their mission of elevating the operational health of America’s healthcare providers. , The ...
(Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million people ... cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world will gather ... Day®. , National Cancer Survivors Day® is an annual worldwide Celebration of Life ...
(Date:5/26/2016)... ... 2016 , ... Dr. James Maisel will present on “Macular ... on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. The presentation ... of New York , is a Board Certified ophthalmologist who completed his fellowship ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... SAN FRANCISCO , May 27, 2016 ... biotechnology company focused on developing products for Regenerative Medicine, Neurology and ... Commissiong will be presenting at two upcoming investor conferences: ... Conference Center, 730 Third Avenue, New York City ... at 3:00pm Marcum MicroCap Conference   ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
Breaking Medicine Technology: